Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Biota Pharmaceuticals Inc    NABI

SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Operates as an anti-infective drug development company

Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections.

Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics, currently being evaluated in ongoing Phase 2b SPIRITUS trial; BTA074, a Phase 2 topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor in Phase 1 development for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment in Phase 2 development for influenza A and B infections.

The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA.
Managers
NameAgeSinceTitle
Joseph M. Patti, PhD522012President, CEO & Executive Director
Russell H. Plumb MBA, CPA572012Executive Chairman
Mark P. Colonnese MBA, CPA602015Chief Financial Officer & Executive Vice President
John H. Vernachio, PhD-2014Vice President-Preclinical Development
Geoffrey F. Cox, PhD722012Independent Non-Executive Director
Anne M. VanLent682013Lead Independent Non-Executive Director
Michael R. Dougherty582013Independent Non-Executive Director
John P. Richard, MBA582013Independent Non-Executive Director
Armando Anido, MBA582015Independent Non-Executive Director
Michael W. Dunne, MD562015Independent Non-Executive Director
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 38,640,487 34,873,116 90.3% 0 0.0% 90.3%
Shareholders
NameEquities%
Broadfin Capital LLC 3,486,711 9.02%
East Hill Management Co. LLC 3,456,520 8.95%
Krensavage Asset Management LLC 2,713,517 7.02%
Senzar Asset Management LLC 1,779,976 4.61%
The Vanguard Group, Inc. 1,044,243 2.70%
Renaissance Technologies LLC 665,158 1.72%
BlackRock Fund Advisors 588,061 1.52%
Fidelity Management & Research Co. 390,000 1.01%
Stonepine Capital Management LLC 347,440 0.90%
Landon Thomas Clay 327,672 0.85%
Sector
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Bio Therapeutic Drugs
Advertisement
Sector Bio Therapeutic Drugs
1st jan.Capitalization (M$)
BIOTA PHARMACEUTICALS ..53
AMGEN, INC.-11.25%105 927
GILEAD SCIENCES, INC.-27.17%95 964
CELGENE CORPORATION-1.78%92 148
REGENERON PHARMACEUTIC..-31.34%39 610
ACTELION LTD40.40%20 855
VERTEX PHARMACEUTICALS..-35.14%19 302
GENMAB A/S32.53%10 276
TESARO INC149.92%6 983
HUALAN BIOLOGICAL ENGI..--.--%4 797
TONGHUA DONGBAO PHARMA..-83.11%4 741
EXELIXIS, INC.200.00%4 732
NEUROCRINE BIOSCIENCES..-17.89%3 755
CHINA BIOLOGIC PRODUCT..-19.42%3 083
ULTRAGENYX PHARMACEUTI..-33.42%3 052
BEIJING SL PHARMACEUTI..--.--%2 985
PEPTIDREAM INC39.82%2 800
GW PHARMACEUTICALS PLC85.37%2 728
BIOCON LTD79.17%2 692
BLUEBIRD BIO INC8.61%2 561
ARIAD PHARMACEUTICALS,..115.68%2 538
Sector Bio Therapeutic Drugs
Biota Pharmaceuticals Inc : Connections
Aviragen Therapeutics, Inc.
2500 Northwinds Parkway
Suite 100
Alpharetta, GA 30009

Phone : +1.678.221.3343
Web : www.aviragen.com
© 2016 People , Fundamentals and Ownership